UniPharma Valuation
Is 6621 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Sales gegen Gleichaltrige
Price-To-Sales gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of 6621 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: Unzureichende Daten zur Berechnung des beizulegenden Zeitwerts von 6621 für die Bewertungsanalyse.
Deutlich unter dem Marktwert: Unzureichende Daten zur Berechnung des beizulegenden Zeitwerts von 6621 für die Bewertungsanalyse.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 6621?
Other financial metrics that can be useful for relative valuation.
What is 6621's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | NT$472.16m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 2.4x |
Enterprise Value/EBITDA | -17.1x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 6621's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 2x | ||
3118 Level Biotechnology | 1.5x | n/a | NT$1.0b |
6130 Shangya Technology | 4.4x | n/a | NT$1.0b |
4173 Arich Enterprise | 1.5x | n/a | NT$1.7b |
4745 Cowealth Medical Holding | 0.4x | n/a | NT$1.8b |
6621 UniPharma | 3.8x | n/a | NT$472.2m |
Price-To-Sales gegen Gleichaltrige: 6621 ist auf der Grundlage des Price-To-Sales Verhältnisses (3.8x) im Vergleich zum Durchschnitt der Vergleichsgruppe (2.9x) teuer.
Price to Earnings Ratio vs Industry
How does 6621's PE Ratio compare vs other companies in the TW Healthcare Industry?
Price-To-Sales gegen Industrie: 6621 ist teuer, wenn man sein Price-To-Sales Verhältnis (3.8x) mit dem TW Healthcare Branchendurchschnitt (1.9x) vergleicht.
Price to Sales Ratio vs Fair Ratio
What is 6621's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 3.8x |
Fair PS Ratio | n/a |
PM vs. Fair Ratio: Unzureichende Daten zur Berechnung der Price-To-Sales Fair Ratio von 6621 für die Bewertungsanalyse.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analysten-Prognose: Unzureichende Daten für eine Preisprognose.